GLP-1 Receptor Agonists for IIH: A Review by Dennis Rivet, MD
GLP-1 RAs Show Promise in Treating Idiopathic Intracranial Hypertension: A New hope for Patients
Table of Contents
For patients battling idiopathic intracranial hypertension (IIH), a condition marked by dangerously high pressure around the brain, treatment options have historically been limited and often carry notable risks. Now,a growing body of evidence suggests a surprising ally in the fight against IIH: medications initially developed for type 2 diabetes and obesity,known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs).New research indicates these drugs may not only promote weight loss - a common suggestion for IIH patients - but could also directly address the underlying neurological issues driving the condition.
Understanding Idiopathic Intracranial Hypertension and Its Challenges
Idiopathic intracranial hypertension, formerly known as pseudotumor cerebri, affects an estimated 1 in 100,000 people, predominantly women of childbearing age. The hallmark of IIH is elevated intracranial pressure, leading to debilitating headaches, vision problems – including potential blindness – and papilledema (swelling of the optic nerve).
Current treatments range from medication to manage symptoms to more invasive procedures like shunts or optic nerve sheath fenestration.Though, these surgical interventions aren’t without their drawbacks. They carry risks of complications and aren’t always effective long-term, leaving a critical need for safer, more scalable therapeutic options.
“We’re dealing with a patient population where traditional surgical treatments are often high-risk or prone to failure,” explains Dennis Rivet, MD, professor and Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University, in a recent interview with NeurologyLive®. “GLP-1 RAs offer a dual opportunity-not only for significant weight loss but potentially for direct neurologic benefit via spinal fluid regulation.”
Groundbreaking Research: GLP-1 RAs Demonstrate Significant Benefits
A recent study, published in JAMA Neurology (Sioutas GS, et al., 2025), provides compelling evidence for the potential of GLP-1 RAs in IIH management. Researchers analyzed data from the TriNetX US Collaborative Network, spanning 2005 to 2024, comparing 555 patients treated with GLP-1 RAs to a matched group of 555 patients who did not receive these medications. The follow-up period for all patients was one year.The results were striking. GLP-1 RA users experienced:
Reduced medication Use: A 47% reduction in the need for other medications (RR, 0.53; 95% CI, 0.46-0.61; P < .001).
fewer Headaches: A 55% reduction in headache frequency and severity (RR, 0.45; 95% CI, 0.35-0.58; P < .001).
Improved Vision: A 40% reduction in the risk of visual disturbances or blindness (RR, 0.60; 95% CI, 0.41-0.88; P = .007).
Decreased Papilledema: An 81% reduction in the incidence of papilledema (RR,0.19; 95% CI, 0.10-0.34; P < .001).
Lower Mortality: A 64% reduction in mortality rates (RR,0.36; 95% CI, 0.18-0.73; P = .003).
Importantly, these benefits were observed regardless of changes in body mass index (BMI) at follow-up (40.6 [SD, 9.2] vs 39.5 [SD, 8.7]; P* = .10), suggesting that GLP-1 RAs may have a direct impact on IIH pathology beyond weight loss.
How Do GLP-1 RAs Work in IIH? Unraveling the mechanism
While the exact mechanisms are still being investigated, researchers believe GLP-1 RAs may influence IIH through several pathways.
Dr.Rivet explains that these medications